A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerchemotherapycisplatinescalationrecurrent
  Phrases that lowered it: evaluate theto evaluateimpairmentopen labelthe study
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 95.6% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 80 (lowers risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports before start: 66564 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 10113 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer NCT01809379 · started 2013 · scored riskier than 38% of active trials completed
• Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors NCT02604784 · started 2015 · scored riskier than 48% of active trials completed
• Intraperitoneal Aerosol Chemotherapy in Gastric Cancer NCT01854255 · started 2013 · scored riskier than 38% of active trials completed
• First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer NCT01669226 · started 2009 · scored riskier than 77% of active trials completed
• p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 NCT03268382 · started 2017 · scored riskier than 76% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.